Phoenix American Announces New Client Partnership with Real Estate Investment Fund Sponsor Capital Square
2 “Strong Buy” stocks that trade at strong discounts
Regardless of whether the markets are moving up or down, every investor loves a bargain. It’s exciting to find a valuable stock at a low price – and then see it appreciate in the medium to long term. The key for investors is finding options where the risk-reward combination works towards long-term benefit. So how are investors supposed to differentiate between the names ready to get back on their feet and those who are supposed to stay in the dumps? That’s what the pros on Wall Street are for. Using TipRanks’ database, we identified two seedy stocks that analysts believe are preparing for a rebound. Despite the heavy losses over the past 52 weeks, the two tickers have received enough street praise to earn a consensus rating of “Strong Buy”. Theravance Biopharma (TBPH) We’re starting Theravance, a biopharmaceutical company focused on developing organ-specific drugs. The current pipeline includes drug candidates for the treatment of inflammatory lung and bowel diseases and neuro-orthostatic hypotension. The research programs range from phase 1 to phase 3 studies. Theravance already has YUPELRI on the market as a COPD treatment. YUPELRI accounts for the lion’s share of Theravance’s sales, reaching $ 18.3 million in the third quarter. This was an increase of 47% over the previous year and a 124% increase in YUPELRI sales. Of greater interest to investors is Trelegy Ellipta, GlaxoSmithKline’s new once-daily inhalation drug developed as a maintenance therapy for asthma and approved by the FDA in September 2020. With this approval, Theravance receives a portion of the income of a drug with a broad potential audience as asthma affects more than 350 million people worldwide. Theravance owns licensing rights to Trelegy with an estimated income of 5.5% to 8.5% of total sales. Trelegy was originally approved in the United States as the first triple once-daily single inhaler therapy for the treatment of COPD. Like many biopharmaceuticals, Theravance has a high overhead and the approved drugs are at the beginning of their profitable lives. This keeps net income and sales low, at least for the short term, and results in a discounted share price – TBPH has declined 32% in the past 52 weeks. Analyst Geoff Porges, who covers the stock for Leerink, remains bullish on Theravance, largely due to the combination of its robust pipeline and approved treatments for lung disease. “Theravance’s respiratory drugs are the top short-term valuation drivers … We are still forecasting ~ $ 2.4 billion in WW triple sales at peak times (2027E). In addition to TBPH’s commercial / partnership assets, the company is also developing an improved JAK inhibitor (JAKi) in collaboration with JNJ (OP) for inflammatory bowel disease (IBD) and a norepinephrine and serotonin reuptake inhibitor (NSRI) TD-9855 (ampreloxetine) for neurogenic orthostatic hypotension (nOH). Each of these drugs uses the novel delivery of unique compounds against proven mechanisms of action and, due to their broader therapeutic window, could offer superior safety and / or treatment effects, ”said Porges. To do this, Porges rates TBPH as outperforming (i.e. buying) and gives it a price target of $ 35, which is an impressive uptrend of 104% for a year. (To see Porges’ track record, click here.) There are 5 total reviews and all are for sale so the consensus on the strong buy is unanimous. TBPH shares are priced at $ 16.95, and their average target price of $ 33.60 indicates an upward movement of 97% from that level. (See TBPH stock analysis on TipRanks) NiSource, Inc. (NI) NiSource is a utility holding company with subsidiaries in the natural gas and electricity sectors. NiSource supplies power and gas to over 4 million customers in Indiana, Kentucky, Maryland, Massachusetts, Ohio, Pennsylvania, and Virginia. The majority of NiSource’s customers, approximately 88%, are in the gas sector. The company’s electrical operations only serve customers in Indiana. The company had third-quarter revenues of $ 902 million, up from $ 962 in the previous quarter and $ 931 in the year-ago quarter. Overall, however, sales have adjusted to the company’s historical pattern: the second and third quarters are relatively low, while return on sales rises with the cold weather in the fourth quarter and highs in the first quarter. This is typical of utility companies in North America. Despite lower year-over-year sales, NiSource was confident enough to maintain its dividend payment and keep it steady at 21 cents per common share through 2020. This corresponds to an annual return of 84 cents and a return of 3.8%. Not only was the company confident of paying returns to shareholders, but also confident of investing heavily in renewable energy sources. The company has an investment plan for fiscal year 20 of more than $ 1.7 billion and expects fiscal year 21 to reach $ 1.3 billion. These expenses are used to finance “green” energy projects. NI is currently trading at $ 21.67, a notable distance from its 52-week low. However, one analyst believes that this lower stock price is an attractive entry point for investors today. Argus analyst Gary Hovis rates NI a Buy along with a price target of $ 32. This number implies an upward movement of 48% from the current level. (To see Hovis’ track record, click here.) “NI stocks appear to be valued cheaply at 18.1 times our EPS estimate for 2021, which is below the average multiple of 21.6 for comparable power companies. and gas supplier, “said Hovis. “NiSource could also become a buyout target as larger utilities and private equity firms have bought smaller utilities because of their stable earnings growth and above-average dividend yields.” Overall, Wall Street sees a clear path for NiSource – a fact that emerges from Strong Buy’s unanimous consensus rating based on three recent buy-side ratings. The shares sell for $ 21.68, and the average target price of $ 28.75 indicates an upside of ~ 32% over the year-ago period. (See NI Stock Research on TipRanks.) To find great ideas for trading rundown stocks at attractive valuations, visit TipRanks’ Best Stocks to Buy, ‘a newly launched tool that brings together all of TipRanks’ stock insights. Disclaimer: The opinions expressed in this article are solely those of the presented analysts. The content is intended to be used for informational purposes only. It is very important that you do your own analysis before making any investment.